J&J looks to ex­pand Ry­bre­vant lung can­cer in­di­ca­tion to larg­er EGFR-pos­i­tive pop­u­la­tion

Just two drugs are ap­proved for NSCLC with EGFR ex­on 20 mu­ta­tions: Take­da’s Exkiv­i­ty and John­son & John­son’s Ry­bre­vant.

But J&J is up­ping the ante, test­ing its NSCLC drug in a more com­mon in­di­ca­tion — pa­tients with EGFR ex­on 19 mu­ta­tions and L858R ac­ti­vat­ing mu­ta­tions who, along­side those with the rar­er ex­on 20 mu­ta­tion, make up the EGFR-pos­i­tive pop­u­la­tion. In an in­ter­im da­ta drop, the phar­ma re­port­ed that af­ter a me­di­an of sev­en months, pa­tients who re­ceived Ry­bre­vant in com­bi­na­tion with oth­er treat­ments had an over­all re­sponse rate of 50%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER